Cargando…

LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations

Individuals with LPIN1 deficiency have early recurrent, life-threatening rhabdomyolysis but the full phenotypic spectrum and optimal treatment of the disorder remains unknown. Here we report the clinical details and treatment outcomes of 6 patients from our health system. The average age of presenta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanderi, Navya, Kirmse, Brian, Regier, Debra S., Chapman, Kimberly A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856908/
https://www.ncbi.nlm.nih.gov/pubmed/35242575
http://dx.doi.org/10.1016/j.ymgmr.2022.100844
_version_ 1784653942760669184
author Kanderi, Navya
Kirmse, Brian
Regier, Debra S.
Chapman, Kimberly A.
author_facet Kanderi, Navya
Kirmse, Brian
Regier, Debra S.
Chapman, Kimberly A.
author_sort Kanderi, Navya
collection PubMed
description Individuals with LPIN1 deficiency have early recurrent, life-threatening rhabdomyolysis but the full phenotypic spectrum and optimal treatment of the disorder remains unknown. Here we report the clinical details and treatment outcomes of 6 patients from our health system. The average age of presentation in our cohort was 23.8 months ±11.6 months (range 15–46 months). The average number of days for each hospitalization for this cohort is 11.7±13.2 days. Creatinine kinase (CK) levels peak during our care averaged 607,725 units/L (range 157,000-1,100,000 units/L). We observed that aspartate aminotransferase levels paralleled the CK levels in its elevation and resolution (Pearson's correlation R = 0.995); while alanine aminotransferase paralleled the elevation but lagged in the resolution of CK levels (R = 0.728). Unlike historical accounts, in our patient population, rhabdomyolysis was sometimes seen without inciting viral or traumatic events. We also cared for multiple individuals that had received treatment at other centers. This allowed us to compare multiple practice approaches and led to a standardized Care Recommendations.
format Online
Article
Text
id pubmed-8856908
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88569082022-03-02 LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations Kanderi, Navya Kirmse, Brian Regier, Debra S. Chapman, Kimberly A. Mol Genet Metab Rep Research Paper Individuals with LPIN1 deficiency have early recurrent, life-threatening rhabdomyolysis but the full phenotypic spectrum and optimal treatment of the disorder remains unknown. Here we report the clinical details and treatment outcomes of 6 patients from our health system. The average age of presentation in our cohort was 23.8 months ±11.6 months (range 15–46 months). The average number of days for each hospitalization for this cohort is 11.7±13.2 days. Creatinine kinase (CK) levels peak during our care averaged 607,725 units/L (range 157,000-1,100,000 units/L). We observed that aspartate aminotransferase levels paralleled the CK levels in its elevation and resolution (Pearson's correlation R = 0.995); while alanine aminotransferase paralleled the elevation but lagged in the resolution of CK levels (R = 0.728). Unlike historical accounts, in our patient population, rhabdomyolysis was sometimes seen without inciting viral or traumatic events. We also cared for multiple individuals that had received treatment at other centers. This allowed us to compare multiple practice approaches and led to a standardized Care Recommendations. Elsevier 2022-02-05 /pmc/articles/PMC8856908/ /pubmed/35242575 http://dx.doi.org/10.1016/j.ymgmr.2022.100844 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Paper
Kanderi, Navya
Kirmse, Brian
Regier, Debra S.
Chapman, Kimberly A.
LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations
title LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations
title_full LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations
title_fullStr LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations
title_full_unstemmed LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations
title_short LPIN1 rhabdomyolysis: A single site cohort description and treatment recommendations
title_sort lpin1 rhabdomyolysis: a single site cohort description and treatment recommendations
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856908/
https://www.ncbi.nlm.nih.gov/pubmed/35242575
http://dx.doi.org/10.1016/j.ymgmr.2022.100844
work_keys_str_mv AT kanderinavya lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations
AT kirmsebrian lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations
AT regierdebras lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations
AT chapmankimberlya lpin1rhabdomyolysisasinglesitecohortdescriptionandtreatmentrecommendations